Hypofractionated radiotherapy is similar to conventional radiotherapy when it comes to health-related quality of life in men with low-risk prostate cancer, according to the RTOG 0415 phase III randomized controlled trial.
Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.
Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.
Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).
Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.
Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.
Progression-free survival should not be used as a surrogate marker for health-related quality of life as there is no correlation between them, results of a systematic review and quantitative analysis of randomized clinical trials show.
Patients who undergo video-assisted thoracoscopic surgery for stage I non-small-cell lung cancer are less likely to become long-term opioid users than their counterparts undergoing the conventional open procedure, findings suggest.
Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.
The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.
The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.
Trial results suggest that cognitive behavioral therapy for insomnia is more effective than acupuncture for reducing the severity of insomnia symptoms in cancer survivors, although both approaches offer benefits.
Patient-reported outcomes and quality of life are better with second-line osimertinib than chemotherapy in patients with T790M-positive advanced non-small-cell lung cancer, shows an analysis of the AURA 3 trial.
Women with early breast cancer have similar quality of life at 5 years whether they are treated with accelerated partial breast irradiation using multicatheter brachytherapy or whole-breast irradiation, GEC-ESTRO data show.
In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.